Development and evaluation of an 18 F-labeled nanobody to target SARS-CoV-2's spike protein
COVID-19, caused by the SARS-CoV-2 virus, has become a global pandemic that is still present after more than two years. COVID-19 is mainly known as a respiratory disease that can cause long-term consequences referred to as long COVID. Molecular imaging of SARS-CoV-2 in COVID-19 patients would be a p...
Saved in:
Published in | Frontiers in nuclear medicine Vol. 2; p. 1033697 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | COVID-19, caused by the SARS-CoV-2 virus, has become a global pandemic that is still present after more than two years. COVID-19 is mainly known as a respiratory disease that can cause long-term consequences referred to as long COVID. Molecular imaging of SARS-CoV-2 in COVID-19 patients would be a powerful tool for studying the pathological mechanisms and viral load in different organs, providing insights into the disease and the origin of long-term consequences and assessing the effectiveness of potential COVID-19 treatments. Current diagnostic methods used in the clinic do not allow direct imaging of SARS-CoV-2. In this work, a nanobody (NB) - a small, engineered protein derived from alpacas - and an Fc-fused NB which selectively target the SARS-CoV-2 Spike protein were developed as imaging agents for positron emission tomography (PET). We used the tetrazine ligation to
F-label the NB under mild conditions once the NBs were successfully modified with
cyclooctenes (TCOs). We confirmed binding to the Spike protein by SDS-PAGE. Dynamic PET scans in rats showed excretion through the liver for both constructs. Future work will evaluate
binding to the Spike protein with our radioligands. |
---|---|
AbstractList | COVID-19, caused by the SARS-CoV-2 virus, has become a global pandemic that is still present after more than two years. COVID-19 is mainly known as a respiratory disease that can cause long-term consequences referred to as long COVID. Molecular imaging of SARS-CoV-2 in COVID-19 patients would be a powerful tool for studying the pathological mechanisms and viral load in different organs, providing insights into the disease and the origin of long-term consequences and assessing the effectiveness of potential COVID-19 treatments. Current diagnostic methods used in the clinic do not allow direct imaging of SARS-CoV-2. In this work, a nanobody (NB) - a small, engineered protein derived from alpacas - and an Fc-fused NB which selectively target the SARS-CoV-2 Spike protein were developed as imaging agents for positron emission tomography (PET). We used the tetrazine ligation to
F-label the NB under mild conditions once the NBs were successfully modified with
cyclooctenes (TCOs). We confirmed binding to the Spike protein by SDS-PAGE. Dynamic PET scans in rats showed excretion through the liver for both constructs. Future work will evaluate
binding to the Spike protein with our radioligands. |
Author | Battisti, Umberto M Rojas-Fernandez, Alejandro Salinas-Varas, Constanza Watterson, Daniel Kramer, Vasko Cheuquemilla, Yorka Lopes van den Broek, Sara Schwefel, David Modhiran, Naphak García-Vázquez, Rocío Shalgunov, Vladimir Amarilla, Alberto A Andersen, Ida Vang Valenzuela-Nieto, Guillermo Jara, Ronald Herth, Matthias M |
Author_xml | – sequence: 1 givenname: Sara surname: Lopes van den Broek fullname: Lopes van den Broek, Sara organization: Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark – sequence: 2 givenname: Rocío surname: García-Vázquez fullname: García-Vázquez, Rocío organization: Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark – sequence: 3 givenname: Ida Vang surname: Andersen fullname: Andersen, Ida Vang organization: Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark – sequence: 4 givenname: Guillermo surname: Valenzuela-Nieto fullname: Valenzuela-Nieto, Guillermo organization: Institute of Medicine, Faculty of Medicine & Center for Interdisciplinary Studies on the Nervous System, CISNE, Universidad Austral de Chile, Valdivia, Chile – sequence: 5 givenname: Vladimir surname: Shalgunov fullname: Shalgunov, Vladimir organization: Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark – sequence: 6 givenname: Umberto M surname: Battisti fullname: Battisti, Umberto M organization: Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark – sequence: 7 givenname: David surname: Schwefel fullname: Schwefel, David organization: Institute of Medical Physics and Biophysics, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany – sequence: 8 givenname: Naphak surname: Modhiran fullname: Modhiran, Naphak organization: Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia – sequence: 9 givenname: Vasko surname: Kramer fullname: Kramer, Vasko organization: Positronpharma SA, Providencia, Santiago, Chile – sequence: 10 givenname: Yorka surname: Cheuquemilla fullname: Cheuquemilla, Yorka organization: Institute of Medicine, Faculty of Medicine & Center for Interdisciplinary Studies on the Nervous System, CISNE, Universidad Austral de Chile, Valdivia, Chile – sequence: 11 givenname: Ronald surname: Jara fullname: Jara, Ronald organization: Institute of Medicine, Faculty of Medicine & Center for Interdisciplinary Studies on the Nervous System, CISNE, Universidad Austral de Chile, Valdivia, Chile – sequence: 12 givenname: Constanza surname: Salinas-Varas fullname: Salinas-Varas, Constanza organization: Institute of Medicine, Faculty of Medicine & Center for Interdisciplinary Studies on the Nervous System, CISNE, Universidad Austral de Chile, Valdivia, Chile – sequence: 13 givenname: Alberto A surname: Amarilla fullname: Amarilla, Alberto A organization: Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia – sequence: 14 givenname: Daniel surname: Watterson fullname: Watterson, Daniel organization: Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia – sequence: 15 givenname: Alejandro surname: Rojas-Fernandez fullname: Rojas-Fernandez, Alejandro organization: Berking Biotechnology, Valdivia, Chile – sequence: 16 givenname: Matthias M surname: Herth fullname: Herth, Matthias M organization: Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39354971$$D View this record in MEDLINE/PubMed |
BookMark | eNqFjrsKwjAUQIMo1kd_Qe7mFIhttekoPnBWcXEoKb2Vapobmljw73XQ2enA4QxnzPqGDPbYKFqlMZdSioCFzt2FEFEqk0gkQxbEWbxMsnQxYtctdqjJNmg8KFMCdko_la_JAFUfAwsJe65VgRpLMMpQQeULPIFX7Q09nNbHE9_QhUdzB87WDwTbksfaTNmgUtph-OWEzfa78-bA7bNosMxtWzeqfeW_m_hv8AboOUEL |
ContentType | Journal Article |
Copyright | 2022 Lopes van den Broek, García-Vázquez, Andersen, Valenzuela-Nieto, Shalgunov, Battisti, Schwefel, Modhiran, Kramer, Cheuquemilla, Jara, Salinas-Varas, Amarilla, Watterson, Rojas-Fernandez and Herth. |
Copyright_xml | – notice: 2022 Lopes van den Broek, García-Vázquez, Andersen, Valenzuela-Nieto, Shalgunov, Battisti, Schwefel, Modhiran, Kramer, Cheuquemilla, Jara, Salinas-Varas, Amarilla, Watterson, Rojas-Fernandez and Herth. |
DBID | NPM |
DatabaseName | PubMed |
DatabaseTitle | PubMed |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2673-8880 |
ExternalDocumentID | 39354971 |
Genre | Journal Article |
GroupedDBID | 9T4 AAFWJ AFPKN ALMA_UNASSIGNED_HOLDINGS EIHBH GROUPED_DOAJ M~E NPM OK1 PGMZT RPM |
ID | FETCH-pubmed_primary_393549713 |
IngestDate | Sat Nov 02 12:21:46 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | COVID-19 SARS-CoV-2 biodistribution nanobodies alpaca tetrazine ligation PET |
Language | English |
License | 2022 Lopes van den Broek, García-Vázquez, Andersen, Valenzuela-Nieto, Shalgunov, Battisti, Schwefel, Modhiran, Kramer, Cheuquemilla, Jara, Salinas-Varas, Amarilla, Watterson, Rojas-Fernandez and Herth. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-pubmed_primary_393549713 |
PMID | 39354971 |
ParticipantIDs | pubmed_primary_39354971 |
PublicationCentury | 2000 |
PublicationDate | 2022-00-00 |
PublicationDateYYYYMMDD | 2022-01-01 |
PublicationDate_xml | – year: 2022 text: 2022-00-00 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in nuclear medicine |
PublicationTitleAlternate | Front Nucl Med |
PublicationYear | 2022 |
SSID | ssj0002784204 |
Score | 4.441281 |
Snippet | COVID-19, caused by the SARS-CoV-2 virus, has become a global pandemic that is still present after more than two years. COVID-19 is mainly known as a... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1033697 |
Title | Development and evaluation of an 18 F-labeled nanobody to target SARS-CoV-2's spike protein |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39354971 |
Volume | 2 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3LS8MwGMCDeBAv4vstOQgeSsaaZul2HNOh4nbwMQYeJEkz0Llm7HHZX--XpF2LD1AvpSSllP7aL1--J0LnPJaKKZu6RemAMMFqRAykJIxp0G65klTZROFOl18_sdt-rV-E27rskpmsqMW3eSX_oQpjwNVmyf6B7PKmMADnwBeOQBiOv2JcivhxToCidLdz76dBWA_aBDjD2pIEqUiNNIlXN10AePDQvH8gLdMj1Nntp-PXoU2cMrYFZlltbdsyB7ZptjWPpLYEsph8ccvfmbGeuj7AIMvgozF6mNucl1E-8Fs51_ylID13Ei5gYVr4GO9syhSmCRtl7eXiTSKCnsiWWdcgDJbLxVy_C9J91a4XFHzuLrFxZMqmDJ-PXNFO2FEeRwR249WyZKYlyRpWo4j7UN4S2fHIobX5xazhe7l8Kp-dT9n6BqCPlOw5b5nblVZtc6b8uk_bC6dmPG6ijWx_gJse9hZa0ek2Wutkr3oHPZeYY2COC-bYDGAEh3W8ZI5z5nhmsGeOC-YXU-yI44z4LjprXz22rol_tJexr0Tykj90tIdWU5PqA4QpaNQxT2LKFWVayUbSkCpkgqtINOqaH6L9H25y9OPMMVq3uLzl6QStziZzfQq62Eyeudf5Ac7zPDw |
link.rule.ids | 314,780,784,4024 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+and+evaluation+of+an+18+F-labeled+nanobody+to+target+SARS-CoV-2%27s+spike+protein&rft.jtitle=Frontiers+in+nuclear+medicine&rft.au=Lopes+van+den+Broek%2C+Sara&rft.au=Garc%C3%ADa-V%C3%A1zquez%2C+Roc%C3%ADo&rft.au=Andersen%2C+Ida+Vang&rft.au=Valenzuela-Nieto%2C+Guillermo&rft.date=2022&rft.eissn=2673-8880&rft.volume=2&rft.spage=1033697&rft_id=info%3Apmid%2F39354971&rft.externalDocID=39354971 |